Navigation Links
New review suggests caution on drugs to raise 'good' cholesterol
Date:8/14/2007

With 40 percent of all heart attacks and related cardiovascular problems occurring in people who have low levels of so-called good cholesterol, researchers have long sought medications to increase the amount of this type of cholesterol in the bodys circulation.

But a new review of 31 randomized controlled trials published in the Journal of the American Medical Association suggests that so far, only modest evidence supports the use of most medications to raise levels of high-density lipoprotein (HDL) good cholesterol. Some are even harmful.

The authors concluded that while efforts to lower low-density lipoprotein (LDL or bad cholesterol) have consistently reduced cardiovascular disease risk, HDL-based approaches are much more complex and sometimes disappointing. As a result, the primary focus should be on LDL, said review co-author Mehdi Shishehbor, D.O., of the Cleveland Clinic.

The news is that not everything that raises HDL will be beneficial, said Ronald Krauss, M.D., spokesman for the American Heart Association and director of atherosclerosis research at Children's Hospital Oakland Research Institute in California.

HDL is a much more complicated issue than LDL, said Prediman Shah, M.D., director of the Atherosclerosis Research Center at Cedars-Sinai Medical Center in Los Angeles. Its not only important how much HDL there is, but what kind it is. Quality is as important as quantity. Is the function good or is it [a form of HDL] that doesnt do the job properly"

There are many types of HDL, not all of which nurture the heart and blood vessels. The good kinds seem to carry fat out of arteries to the liver and perform functions in cell membranes and elsewhere. However, HDLs vary considerably in size, density and other chemical properties that change their ability to sustain health.

Certain kinds of HDL could even increase inflammation, clogging arteries rather than clearing them, and doctors currently do
'/>"/>

Contact: Lisa Esposito
hbns-editor@cfah.org
Center for the Advancement of Health
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. FDA may speed review of new drugs
2. Scientists review SARS
3. US Reviews Risks Of Tamiflu After 12 Children Die
4. Breast Cancer Examinations To Be Reviewed In Irish Hospitals
5. BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD
6. A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm
7. Thumbs up in weight loss for vegetarian diets: scientific review
8. FDA Accords Priority Review For Pediatric Crohns Disease Drug
9. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
10. Review of Pramod Mahajans Injuries
11. Vaticans Council Reviews Condom Usage

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)... high cost of drug advertising that does little to...iversity of British Columbia health policy researc...ves of Internal Medicine , examined the US sales p...own by the trade name Plavix used to prevent blood...selected to study the impact of advertising on sal...
(Date:11/23/2009)... from women,s hair loss for almost ten years, Zsan...ng her progress and the secret behind her success ...of her video diaries which include a direct compar... , (PRWeb UK) November 23,...klosi has released the video diaries that document...
(Date:11/23/2009)...se the problem, researchers say , , MOND...their anger over unfair treatment at work could be...es. , Men who consistently failed to express th... or supervisor were more than twice as likely to h...e who vented their anger, claims a report in the N...
(Date:11/23/2009)...stCall/--InfoLogix,Inc.(Nasdaq: IFLG ),aleadingtec...healthcareandcommercialindustries,announcedtodayth...mensHealthServices,hasjoinedInfoLogixasVicePreside...://www.newscom.com/cgi-bin/prnh/20090618/NE35135LO...vicesforInfoLogix,Mr.Waywillberesponsiblefortheful...
(Date:11/23/2009)...wswire/--TheAmericanSocietyofHematology(ASH)andSch...dmediacompany,arelaunching"ExploretheMysteryofBloo...tinthefieldsofscienceandmedicine,inadditiontoexpos...gy. ,, "Manyhematologistsmayrememberwatchingaca...elearningaboutbloodreallyfun,"statedNancyBerliner,...
Breaking Medicine News(10 mins):Health News:Drug ads ineffective for boosting sales, could cost taxpayers: UBC-Harvard study 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 2Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 3Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 2Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 3Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 2Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 3
...4 CryoCor, Inc. (Nasdaq:,CRYO), a medical device ...hmias, announced today the publication of a Europe...ith CryoCor,s Cardiac Cryoablation System.,The pur...cused on isolating the pulmonary veins to treat th...
...utes of counseling helped people cut down on exces... -- Even a little counseling on the dangers of alc...n help problem drinkers cut back by at least three...t to almost 7,800 emergency patients in 14 univers...
...Jan. 2 Watson,Pharmaceuticals, Inc. (NYSE: WPI )...unced today that it has received final approval fr...ration (FDA) on its Abbreviated,New Drug Applicati...Sulfate product is the,generic equivalent to Dey, ...
...Jan. 2 Barr Pharmaceuticals,Inc. (NYSE: BRL ) to...es,Inc. has received final approval from the U.S. ... version of Roche Laboratories Inc.,s KYTRIL(R),(g...8, 2007, and plans to launch its product shortly.,...
... Mo. An estimated 750,000 hospitalized patients ..., and less than 30 percent of those leave the hosp...3 issue of the New England Journal of Medicine, re...c arrest known as ventricular arrhythmia. They fou...
...ncludes special deal and free unique support chann...YSE: MED ) today announced that the Company is of...closed Pure Weight Loss centers. Medifast is,offer...fast is also offering former Pure Weight Loss clie...
Other Medicine News:Health News:CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation 2Health News:CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation 3Health News:Brief Chat With ER Docs Can Curb Problem Drinking 2Health News:Watson Receives FDA Approval for Generic DuoNeb(R) 2Health News:Barr Receives Approval for Generic KYTRIL(R) Tablets, 1mg (Base) 2Health News:Barr Receives Approval for Generic KYTRIL(R) Tablets, 1mg (Base) 3Health News:For hospital patients, defibrillation delays mean lower survival 2Health News:Medifast Offers Stranded Pure Weight Loss Clients Unique Options 2Health News:Medifast Offers Stranded Pure Weight Loss Clients Unique Options 3
(Date:11/23/2009)...INTRICHMOND,Calif.,Nov.23/PRNewswire-FirstCall/--T...nouncedthatitisscheduledtomeetwiththeU.S.FoodandDr...ompleteResponseLetterregardingtheNewDrugApplicatio...ingualtablet).Aspreviouslyannounced,theCompleteRes...dicatedthattheFDAcouldnotapprovetheNDAinitspresent...
(Date:11/23/2009)...MBRIDGE,Mass.,Nov.23/PRNewswire/--LigonDiscovery,I...hnologytofinddrugsagainsthigh-valuetargets,todayan...anErrolB.DeSouzaasLigon,sExecutiveChairmanoftheBoa...ecutiveChairmanoftheBoard,"saidPatrickKleyn,Ligon,...,sbreadthofexperienceinthelifesciencesindustry--pa...
(Date:11/23/2009)...llowingtheFDAapprovalsoftwonewtherapiesforNon-Hodg...nupdatedtoincludeofatumumab(Azerra(TM),GlaxoSmithK...yticleukemia(CLL)andromidepsin(Istodax(R),Gloucest...withcutaneousT-celllymphoma(CTCL). ,, FORTWASHI...FDAapprovalshavepromptedtheNationalComprehensiveCa...
Breaking Medicine Technology:Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter 2Ligon Discovery Announces Appointment of Errol B. De Souza as Executive Chairman 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 3CEL SCI Corporation to Raise 2420 Million in Registered Direct Offering 57405 1CEL SCI Corporation to Raise 2420 Million in Registered Direct Offering 57405 2CEL SCI Corporation to Raise 2420 Million in Registered Direct Offering 57405 3Prescient Medical vProtect 28TM 29 Luminal Shield Receives North American Product Innovation of the Year Award from Frost 26 Sullivan 57403 1Prescient Medical vProtect 28TM 29 Luminal Shield Receives North American Product Innovation of the Year Award from Frost 26 Sullivan 57403 2PharmAbcine Closes USD 246 Million Series A Financing 14102 1PharmAbcine Closes USD 246 Million Series A Financing 14102 2PharmAbcine Closes USD 246 Million Series A Financing 14102 3PharmAbcine Closes USD 246 Million Series A Financing 14102 4
...ME TSX: COM, VANCOUVER and DEERFIELD, IL, June 04,...p. and its,co-development partner Astellas Pharma ... their recently completed Phase 3 clinical,study, ... safety of,the intravenous formulation of vernakal...atment of patients who developed,atrial fibrillati...
...ent Ever to Demonstrate Significant Survival Benef...wswire-FirstCall/ -- Bayer,HealthCare Pharmaceutic...unced that Nexavar(R) (sorafenib) tablets signific...epatocellular carcinoma,(HCC), or primary liver ca...p-value=0.0006). Results were presented at the 43r...
Other Medicine Technology:Cardiome And Astellas Announce Positive Results From ACT 2 Trial 2Cardiome And Astellas Announce Positive Results From ACT 2 Trial 3Cardiome And Astellas Announce Positive Results From ACT 2 Trial 4Cardiome And Astellas Announce Positive Results From ACT 2 Trial 5Cardiome And Astellas Announce Positive Results From ACT 2 Trial 6Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 2Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 3Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 4Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 5Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 6Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 7
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
Medicine Products: